about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Foamix stock bub­bles high­er on lat­est ac­ne PhI­II; Con­cen­tric Anal­gesic gets an FDA 'break­through'

7 years ago
News Briefing

Pfiz­er, Mer­ck KGaA tout PhI­II suc­cess for Baven­cio; Im­mun­sanT gets a new in­vest­ment from JDRF

7 years ago
News Briefing

NHS re­fus­es to cov­er Ocre­vus for pri­ma­ry pro­gres­sive MS; OxStem taps vet­er­an drug hunter Georg Ter­stap­pen as CSO

7 years ago
News Briefing

Chi­na reg­u­la­tors launch a re­view for BeiGene’s PD-1; PureTech co-founder hops to Long­wood Fund

7 years ago
News Briefing

Pfiz­er inks mar­ket­ing deal for col­orec­tal can­cer test; Zai Lab dous­es a hot ru­mor about a Hong Kong IPO

7 years ago
News Briefing

Cel­lec­tar climbs (then sinks) on PhII DL­B­CL da­ta; Vyr­i­ad inks deal with Pfiz­er/Mer­ck KGaA

7 years ago
News Briefing

Idera shares slide on PhII fail­ure; WuXi blue­prints $60M man­u­fac­tur­ing cen­ter in Worces­ter, MA

7 years ago
News Briefing

Vi­su­al­ize: AS­CO 2018's win­ners and losers

7 years ago
R&D
Pharma

Roche gets pri­or­i­ty re­view for Hem­li­bra's sec­ond in­di­ca­tion; Ora­sis gets $13M B round for pres­by­opia eye drop

7 years ago
News Briefing

Fin­land's Faron ham­mered by sur­pris­ing piv­otal tri­al flop; CFO Si­mon Dinge­mans ex­its GSK in lead­er­ship makeover

8 years ago
News Briefing

Sofinno­va leads $32.4 mil­lion round for Italy's Ery­Del; Cel­gene ex­pands col­lab­o­ra­tion with Zymeworks

8 years ago
News Briefing

The un­der-40s: How does the next gen­er­a­tion of bio­phar­ma ex­ec­u­tives view the fu­ture?

8 years ago
People
Special

Bris­tol-My­ers of­fers some ea­ger­ly await­ed Check­mate-227 re­sults, but they're not chang­ing med­ical prac­tice -- yet

8 years ago
R&D

Video: How many PD-1/L1 drugs do we need? Where is im­munother­a­py head­ed? Watch Jay Brad­ner, Hervé Hop­penot, Ellen ...

8 years ago
Special
Pharma

Rare obe­si­ty dis­ease play­er Rhythm Phar­ma sets out in search of a $115M IPO wind­fall

8 years ago
Financing

Or­biMed lines up $551M gam­ble on Chi­na, In­dia biotech sec­tors

8 years ago
Financing

Al­ler­gan vet In­gram takes the helm at Sarep­ta; Big Phar­ma alum­ni Cather­ine Steele is the new comms chief at Bio­gen

8 years ago
Peer Review

Op­ti­miz­ing clin­i­cal out­comes for chal­leng­ing mol­e­cules with lipid-based drug de­liv­ery

8 years ago
R&D

Peer Re­view: For­mer FDA Com­mish Califf will split his time be­tween Ver­i­ly and Duke

9 years ago
Peer Review

Al­ny­lam adds a slate of new ex­ec­u­tives; Thomas In­sel is leav­ing Ver­i­ly; Akari CEO Gur Rosh­walb placed on leave

9 years ago
Peer Review

Scott Got­tlieb is sworn in as FDA com­mis­sion­er

9 years ago
Pharma

Mer­ck vet Robert Plenge moves to Cel­gene, Grit­stone re­cruits a Genen­tech star and more

9 years ago
Peer Review

A biotech bil­lion­aire tops the list of the 15 high­est paid R&D ex­ecs in bio­phar­ma

9 years ago
People

No­var­tis vet named CMO at Rgenix; Oph­thotech pro­motes Sblendo­rio to CEO spot

9 years ago
Peer Review
First page Previous page 2324252627 Next page Last page
A service from the Financial Times